Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino-acid neuropeptide hormone belonging to the glucagon/secretin superfamily. It is widely distributed in the body, including the gut, pancreas, central and peripheral nervous systems. VIP acts primarily through two class B G protein-coupled receptors—VPAC1 and VPAC2—to mediate diverse physiological effects such as vasodilation, smooth muscle relaxation (notably in the gastrointestinal tract), stimulation of water and electrolyte secretion from exocrine glands (pancreas and bile), inhibition of gastric acid secretion, modulation of immune responses via anti-inflammatory actions, enhancement of glucose-dependent insulin secretion from pancreatic β-cells, promotion of β-cell proliferation, neuroprotection in the CNS, regulation of circadian rhythms via action on suprachiasmatic nuclei neurons in the brain, and cardiovascular effects including coronary vasodilation[4][5][6][8]. Synthetic forms like Aviptadil have been developed for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on vasoactive intestinal peptide.